Stability Genius: How CMC Section Of COVID-19 Vaccine Guidance Speeds EUAs Safely
Executive Summary
By focusing on short-term stability, US FDA paves way for quicker emergency use authorization without compromising on quality.
You may also be interested in...
Wait For Stability Results Before Moving Expiring COVID-19 Vaccine, Woodcock Says
Acting FDA Commissioner Janet Woodcock says stability studies are ongoing and that states shouldn’t get rid of expiring inventory yet.
Need For Advanced Manufacturing Technologies A ‘Great Learning’ From The Pandemic, CBER’s Marks Says
COVID-19 highlighted limited domestic capacity and need for more flexibility, agility and reliability in manufacturing processes, says FDA biologics center director Peter Marks; he also discussed differences in data review for vaccine BLAs relative to EUAs.
A Pandemic Template For Swift Approval? Veklury Stability Questions Deferred For Later Study
The US FDA shaved months from review of Gilead’s Veklury (remdesivir) for COVID-19 with post-approval commitments for multiple stability studies. The Pink Sheet takes a deep dive look at discussions within the agency and with the sponsor.